written on 05.05.2014

Pfizer's 'weak' Q1 numbers bolster case for AZ buy–and post-merger split, too


Pfizer has pulled back the veil on its three new operating segments. It's the long-awaited peek at these units, created last July as a prelude to potential sales or spin-offs. Do the numbers bear out analyst enthusiasm for more Pfizer split-up action?